Jun 08, 2022 / 02:30PM GMT
Peter James Welford - Jefferies LLC, Research Division - Senior Equity Analyst & European Pharmaceuticals Analyst
Okay. Good morning, everyone. If you find your seats, please. My name is Peter Welford. I'm the European Life Sciences Pharma and Biotech Analyst at Jefferies in London. My great pleasure to have the next company here in the track today, which is QIAGEN. And it's our pleasure to have with us here today, Roland Sackers, the CFO; and also John Gilardi from the Investor Relations team.
I'll let Roland make a make a few sort of comments, but perhaps in particular, we'll see those start off as well talking about COVID-19 and I guess we'd ask at the start maybe, by all means for you to say a few comments about the company, but particularly as well, can you just talk a little bit about, I think what's become your catch phrase that you are COVID-19 relevant, but not COVID-19-dependent. So perhaps you can go from there and yes, over to you, and we'll kick off with -- maybe you want to make a few introductory comments.
Roland Sackers - Qiagen N.V. - CFO, MD &
Qiagen NV at Jefferies Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers